Cellectar Biosciences, Inc. · NASDAQ:CLRB

Cellectar Biosciences — EMIT: Targeted Radiotherapy Conference 2013

27 slides from Cellectar Biosciences's conference presentation, Jan 31, 2013

  1. Slide 1: Cancer-Targeted Diapeutics

    ™ Cancer-Targeted Diapeutics Radioiodinated Phospholipid Ether Analogs for Broad-Spectrum Imaging and Therapy EMIT: Targeted Radiotherapy Conference Washington, DC January 31, 2013

  2. Slide 2: Cancer-Targeted Approaches: Desirable Features

    Cancer-Targeted Approaches: Desirable Features o Selective for cancer vs. normal cells/tissues o Broad-spectrum targeting across/within cancer types o Targets cancer stem cells and mature cancer cells o Targeting vehicle can deliver a range of effectors (radioisotopes, chemo agents, imaging agents)

  3. Slide 3: Cancer-Targeted, Broad-Spectrum, Multi-Product Technology Platform

    Cancer-Targeted, Broad-Spectrum, Multi-Product Technology Platform Cancer-Targeting Mechanism PLE [portal of entry] Cancer-targeted Lipid Raft Cancer-targeted Radiopharmaceuticals Optical Imaging Cell Membrane PET Therapy Intraoperative Margin Imaging Illumination & +  Phospholipid Catabolism Non-I

  4. Slide 4: Cancer-Targeting Technology Platform

    Cancer-Targeting Technology Platform Cancer Cancer Targeting Killing/Imaging hydrophilic R hydrophobic phospholipid ether analog = PLE F N R = *I F B N N N 124I-CLR1404 - PET 131I-CLR1404 - Radiation therapy CLR1501 CLR1502 127I-CLR1404 - Chemotherapy Optical, visible Optical, near-infrared o Propri

  5. Slide 5: PLEs Selectively Target Cancer Cells

    PLEs Selectively Target Cancer Cells Co-Culture o PLEs accumulate in cancer vs. normal cells Green = CLR1501 Hu Prostate PC3 Blue = cell nucleus (24 hr incubation) Cancer Normal Hu NFA Fibroblast Normal Melanoma Uterine Pancreatic Colorectal Ovarian Glioma Fibroblast Normal fibroblast Prostate 12.0*

  6. Slide 6: Lipid Rafts

    Lipid Rafts Cholesterol Extracellular Glycosphyngolipid Intracellular Signaling Lipid Raft protein o Lipid rafts are specialized microdomains of plasma membrane that are enriched in cholesterol and glycosphingolipids o Lipid rafts serve as molecular platforms that spatially organize molecules for sp

  7. Slide 7: Lipid Rafts are Over-Expressed in Cancer Cells

    Lipid Rafts are Over-Expressed in Cancer Cells • PLE uptake into cancer cells is, at least in part, dependent upon intact plasma membrane lipid rafts Co-Culture Prostate Pancreatic NSCLC Normal Hu Fibroblast Intact Rafts Disrupted Rafts Kidney NSCLC (Me-β-cyclodextrin Hu NSCLC pretreatment) cell (re

  8. Slide 8: Reduced PLE Catabolism in Neoplastic Cells/Tissues May Contribute to Retention

    Reduced PLE Catabolism in Neoplastic Cells/Tissues May Contribute to Retention PLE Catabolic PLD b PLD Tissue Cell/Tissue Activity a Protein c mRNA d Rat Liver (normal) 7.3 Rat Liver (normal) 14.1 12.2 RatMorris Hepatoma 7794A 5.8 Mouse CT26 RatMorris Hepatoma 7777 1.4 7.8 2.4 colorectal Mouse Sarco

  9. Slide 9: PLEs Selectively Target a Wide Range of Malignant Tumors In Vivo

    PLEs Selectively Target a Wide Range of Malignant Tumors In Vivo Yes Selective Uptake No & Retention of (52) 124I-CLR1404 (2) Human cancer Rodent malignant tumors Mouse benign xenografts tumors Breast Glioma Intestinal polyp Prostate Prostate * Retinoblastoma Non-small cell lung Mammary alveolar Col

  10. Slide 10: PLEs Selectively Target a Wide Range of Malignant Tumors In Vivo

    PLEs Selectively Target a Wide Range of Malignant Tumors In Vivo Representative nuclear and/or microPET/CT or MRI hybrid images demonstrating excellent primary and metastatic tumor conspicuity. Images were acquired from 24-96h post-i.v. injection (80-140 µCi of 124I-CLR1404) in a variety of human su

  11. Slide 11: CLR1404 Tumor Uptake/Retention In Vivo

    CLR1404 Tumor Uptake/Retention In Vivo 124I-CLR1404 - PC3 hu prostate xenograft (µPET scans) 6h 24h 48h 72h 120h Fiducial Head Tumor uptake evident at about 9h markers Movies 125I-CLR1404 - 251 hu adrenal xenograft Head 11

  12. Slide 12: Unlike FDG, CLR1404 Does Not Accumulate at Sites of Inflammation

    Unlike FDG, CLR1404 Does Not Accumulate at Sites of Inflammation 18F-FDG (110 min t1/2) 124I-CLR1404 (4 day t1/2) I H T Tibia T Movie Movie 24h 1h PC3 human prostate xenograft I = carrageenan induced inflammatory lesion, H = heart, T = tumors 12

  13. Slide 13: CLR1404 Targets Primary and Metastatic Tumors

    CLR1404 Targets Primary and Metastatic Tumors 3D Hybrid microPET/CT image of an anesthetized orthotopic BxPC3 pancreatic tumor-bearing Nude mouse 48h post iv M administration of 124I-CLR1404, The presence of the primary P pancreatic tumor (P) as well as a spontaneous liver metastasis (M) is evident

  14. Slide 14: PLEs Target Cancer Stem Cells

    PLEs Target Cancer Stem Cells o Growing database implicates cancer stem cells in  Tumor growth, metastasis  Resistance to chemotherapy, radiotherapy  Cancer relapse Normal Hu Normal Hu Human Glioma Human Glioma Astrocytes 1.0* Neuronal Stem Cells Cells 6.0* Stem Cells 8.0* 1.3* * fluorescent sign

  15. Slide 15: 131I-CLR1404 is Highly Efficacious in Mouse Xenograft Models

    131I-CLR1404 is Highly Efficacious in Mouse Xenograft Models Ovarian Colorectal Renal Trip Neg Breast 1.0 Ovarian CA I-127-CLR1404 1.0 I-127-CLR1404 I-131-CLR1404 1.0 Renal Cell CA I-127-CLR1404 1.0 I-131-CLR1404 I-131-CLR1404 0.8 0.8 0.8 0.8 0.6 0.6 0.6 0.6 Survival Survival Survival Survival 0.4 0

  16. Slide 16: The Diapeutic Cancer Treatment Paradigm

    The Diapeutic Cancer Treatment Paradigm o A major goal of oncology today is to predict which patients will respond to a molecularly targeted drug  This is done by using biomarkers or imaging surrogates which are selective for the pathway or target of interest  Limitations of imperfect surrogates o

  17. Slide 17: 124/131I-CLR1404 Diapeutic Paradigm

    124/131I-CLR1404 Diapeutic Paradigm o PET/CT time course of an LS180 colon CA xenograft-bearing mouse injected i.v. with a single injection of a mixture of 124,131I-CLR1404 (200 µCi each). Tumor shrinkage confirmed by CT. Weight loss seen near the end of the study. 3 Hours* 1 Day 3 Days 5 Days 7 Day

  18. Slide 18: CLR1404 Platform – Clinical Studies

    CLR1404 Platform – Clinical Studies o 124I-CLR1404 PET imaging agent  Ongoing Phase 1-2 trials in multiple tumor types • NSCLC, brain (primary and metastases), triple negative breast, soft tissue sarcoma, colorectal, gastric, esophageal, prostate, ovarian, pancreatic, and head & neck cancers o 131I

  19. Slide 19: 124I-CLR1404 PET - NSCLC Brain Tumor Metastases

    124I-CLR1404 PET - NSCLC Brain Tumor Metastases o Three previously unknown brain mets were discovered, altering treatment plan o Selective tumor uptake against very low background in normal brain tissue Movie Imaged 6 days following a 5 mCi dose; confirmed with MRI

  20. Slide 20: 124I-CLR1404 PET – Recurrent Glioblastoma

    124I-CLR1404 PET – Recurrent Glioblastoma o 124I-CLR1404 PET image shows tumor to brain ratio of 30:1 (3-5 typically considered adequate in PET imaging) T1-MRI PET T1-MRI PET 18F-DOPA PET 124I-CLR1404 PET JNM Cover Image 48h post-5mCi dose Walter F, et al, J Nuc Med, March, 2012, 53:393 20

  21. Slide 21: 124I-CLR1404 PET - Glioblastoma

    124I-CLR1404 PET - Glioblastoma o 124I-CLR1404 PET and MRI tumor images are only partially overlapping o This could reflect more accurate imaging of living, malignant tissue by 124I- CLR1404 PET compared to MRI (note: histopathology not performed on resected tumor) 124I-CLR1404 PET Possible MRI (48h

  22. Slide 22: 124I-CLR1404 PET – No Uptake in Glioma Scar Tissue

    124I-CLR1404 PET – No Uptake in Glioma Scar Tissue o 124I-CLR1404 PET has the potential to differentiate growing tumor from pseudoprogression, enabling more timely and certain diagnosis Prior radiation therapy No 124I-CLR1404 uptake scarring MRI 124I-CLR1404 PET (day 2 post-dose, 5 mCi) 22

  23. Slide 23: 131I-CLR1404 PET – Targets Tumors in Man

    131I-CLR1404 PET – Targets Tumors in Man o SPECT/CT images from Phase 1a dosimetry study (10 mCi, Day 6) o Demonstrated uptake and prolonged retention of 131I-CLR1404 in cancerous tumors but not normal tissues Prostate Cancer Metastases in Colorectal Cancer Lumbar, Spine, Pelvis, Sacrum Pulmonary Me

  24. Slide 24: 131I-CLR1404 PET – Targets Tumors in Man

    131I-CLR1404 PET – Targets Tumors in Man o SPECT/CT images from Phase 1b MTD study (27 mCi, Day 21) o Demonstrated uptake and prolonged retention of 131I-CLR1404 in cancerous tumors but not normal tissues Liver, with mets Pulmonary Pulmonary met met Liver, with mets Pulmonary met Colorectal cancer p

  25. Slide 25: CLR1502 - Intraoperative Tumor Margin Illumination and Non-Invasive Tumor Imaging

    N CLR1502 - Intraoperative O Tumor Margin Illumination and (CH2)18OPOCH2CH2N(CH3)3 O Non-Invasive Tumor Imaging N IVIS® Fluobeam TM (near-IR) Fluobeam ™ Fluoptics No residual tumor Intraoperative Tumor Non-Invasive Tumor Imaging Margin Illumination in Real Time HCT116 human colon tumor xenograft; 4

  26. Slide 26: Summary

    Summary o Overabundant lipid rafts and deficits in PLE catabolism are believed to be involved in selective targeting of both differentiated cancer cells and cancer stem cells by PLEs o As a consequence, PLE targeting of primary and metastatic tumors is broad-spectrum across a wide range tumor types

  27. Slide 27: Thank you!

    Thank you! Novelos Colleagues UW Students and Faculty Univ Wisconsin Jamey Weichert Fred Lee Carbone Cancer Center Chris Blakley Perry Pickhart Radiology Maria Dawson Sharon Weber Medical Physics Andrea Flaherty Anne Traynor Human Oncology Patrick Genn Rock Mackie WARF Joe Grudzinski John Kuo Clinic

Cellectar Biosciences — EMIT: Targeted Radiotherapy Conference 2013 on 6ix